• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MSCS receives Alzheimer’s grant

MSCS receives Alzheimer’s grant

July 6, 2011
CenterWatch Staff

Metabolic Solutions Development Company has received a $773,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to conduct a pilot phase II trial of MSDC-0160, MSDC’s compound for the treatment of metabolic diseases associated with altered mitochondrial function.

“MSDC-0160 is a novel insulin sensitizer that modulates mitochondrial metabolism.  Growing evidence suggests that loss of mitochondrial function and decline in brain glucose metabolism could be a contributing cause of Alzheimer’s disease.  This study will help us determine if MSDC-0160 affects glucose utilization in specific regions of the brain and determine the feasibility of conducting future large-scale clinical studies in patients with mild Alzheimer’s disease,” said Jerry Colca, president and chief scientific officer of MSDC.

The double-blind, placebo-controlled study will involve patients ages 55-85 diagnosed with mild Alzheimer’s disease.  Up to 50 patients will be randomized to receive either MSDC-0160 (150 mg) or placebo once daily for 90 days.  The effects of MSDC-0160 on brain glucose utilization (measured by FDG-PET) and the safety profile of the compound will be analyzed in addition to global cognitive function.  The study will be performed at Rush University Medical Center in Chicago. The principal investigator is Raj C. Shah, M.D., medical director of the Rush Memory Clinic at the Rush Alzheimer’s Disease Center. Analysis of brain glucose utilization will be performed in collaboration with the innovative imaging company Abiant.



Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing